Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Investigating the role of lytic Epstein-Barr virus reactivation in Multiple Sclerosis

FY 2022-23

Summary
Multiple sclerosis (MS) is an autoimmune disease that impacts 2.5 million people worldwide. The disease is characterized by autoreactive immune cells that mount a response against components of the central nervous system, namely the brain and spinal cord, leading to physical, cognitive, and neurological decline. There is currently no cure for MS, and the cause of the disease is unknown, though it is thought to be a combination of genetic and environmental factors. Among the putative environmental agents, infection with Epstein-Barr virus (EBV) is a top candidate. The mechanism by which EBV increases the risk of MS remains unknown. EBV is a common virus that infects over 90% of the world’s population. Following primary infection, EBV establishes a life-long latent (dormant) infection in the host’s B cells. Under certain conditions, the virus can reactive to a lytic (replicative) state. Defects in the control of EBV lytic reactivation have been suggested as a trigger for the development of MS, but the supporting evidence is inconsistent. Therefore, the objective of this project is to elucidate the role of EBV lytic reactivation in MS using a humanized mouse model for MS. Briefly, immunocompromised mice will be engrafted with immune cells from human donors previously infected with EBV, and histone deacetylase inhibitors will be used to initiate the reactivation of EBV from the latent to the lytic state. A validated mouse model for MS will then be induced and clinical and immunological outcomes will be assessed. This work will help inform the current controversies for the role of EBV reactivation in clinical presentations of MS and will contribute preliminary evidence for whether specifically targeting EBV-infected cells could provide a novel treatment strategy for MS.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486215
Name
Rosen Ariel
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of lytic Epstein-Barr virus reactivation in Multiple Sclerosis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adaptive Immunity; Central Nervous System; Epstein-Barr Virus; Experimental Autoimmune Encephalomyelitis; Humanized Mice; Inflammation; Multiple Sclerosis; Peripheral Blood Mononuclear Cells; Viral Induced Autoimmunity; Viral Reactivation
Abstract
Multiple sclerosis (MS) is an autoimmune disease that impacts 2.5 million people worldwide. The disease is characterized by autoreactive immune cells that mount a response against components of the central nervous system, namely the brain and spinal cord, leading to physical, cognitive, and neurological decline. There is currently no cure for MS, and the cause of the disease is unknown, though it is thought to be a combination of genetic and environmental factors. Among the putative environmental agents, infection with Epstein-Barr virus (EBV) is a top candidate. The mechanism by which EBV increases the risk of MS remains unknown. EBV is a common virus that infects over 90% of the world’s population. Following primary infection, EBV establishes a life-long latent (dormant) infection in the host’s B cells. Under certain conditions, the virus can reactive to a lytic (replicative) state. Defects in the control of EBV lytic reactivation have been suggested as a trigger for the development of MS, but the supporting evidence is inconsistent. Therefore, the objective of this project is to elucidate the role of EBV lytic reactivation in MS using a humanized mouse model for MS. Briefly, immunocompromised mice will be engrafted with immune cells from human donors previously infected with EBV, and histone deacetylase inhibitors will be used to initiate the reactivation of EBV from the latent to the lytic state. A validated mouse model for MS will then be induced and clinical and immunological outcomes will be assessed. This work will help inform the current controversies for the role of EBV reactivation in clinical presentations of MS and will contribute preliminary evidence for whether specifically targeting EBV-infected cells could provide a novel treatment strategy for MS.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rosen, Ariel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~